Project Grant R41HL115965

This $480,990 Project Grant awarded by the National Heart, Lung, and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) aims to establish the central role of a recently identified lung cell type, "aerocytes," in regulating alveolar regeneration following lung injury. The research proposal has two key objectives: Investigate the role of aerocyte-derived R-spondin3 in lung growth and recovery using animal studies within disease-related lung injury models....

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $684,814 to The Regents of the University of California, San Francisco (UCSF) to conduct research on the suppression of alveolar stem cells by tissue-resident lymphocytes in emphysema. The research aims to investigate how tissue factors in the lung alter the inflammatory response to viral infections, leading to the loss of alveolar type 2...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $657,308 to The Children's Hospital of Philadelphia (CHOP) to conduct research on the CXCL12 signaling axis and its role in pulmonary arterial heterogeneity, development, and disease. The key objectives of this 12-month project are to: 1) define the spatiotemporal role of CXCL12 signaling in pulmonary vascular development, 2)...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $166,752 to Boston Medical Center Corporation to develop models of placenta-driven developmental lung injury in human preeclampsia. The 5-year project aims to characterize the influence of human preeclampsia on fetal lung development. Specifically, the research will: 1) Identify preeclampsia-specific placental proteins in the fetal circulation that...

The University of Southern California (USC) Department of Contracts and Grants Division received a $413,958 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The purpose of this 1-year award, effective September 22, 2023, is to investigate the role of the protein PUMA in promoting cell death and inflammation in chronic obstructive pulmonary disease (COPD) caused by cigarette smoke exposure. The research aims...

This Project Grant award of $258,516 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) will fund research to better understand the role of mitochondrial-derived peptides (MDPs) in the development of chronic obstructive pulmonary disease (COPD). The University of Pittsburgh will utilize the NHLBI BIOLINCC repository to analyze plasma and lung tissue samples to characterize changes in MDPs across COPD disease severity. They will combine...

This Project Grant award of $389,754 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to assess the therapeutic potential of a peptide derived from collagen XVIII for treating lung fibrosis associated with systemic sclerosis (scleroderma). The project aims to evaluate the anti-fibrotic effects of this peptide in a murine model of lung fibrosis, as well as identify the minimal effective dose, optimal...

This federal Project Grant award, funded by the National Heart, Lung, and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports research into the role of the hedgehog pathway and primary cilia axis in human lung alveologenesis and diseases such as bronchopulmonary dysplasia (BPD). The $156,168 grant awarded to the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center will fund a 2-year study examining the cellular and molecular...

The Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $268,500 to Brigham & Women's Hospital Inc. to develop and validate a quantitative marker of pulmonary microvascular injury and explore the correlation between microvascular volume loss and the longitudinal progression of chronic obstructive pulmonary disease (COPD) and emphysema in smokers. The research leverages an AI-based algorithm to assess vascular...

This Project Grant award of $1,410,668 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to investigate the mechanistic roles of cyclin-dependent kinase 9 (CDK9) in idiopathic pulmonary fibrosis (IPF) and validate CDK9 as a new anti-inflammatory and anti-fibrotic pharmacotherapeutic target for treating IPF. The research is being conducted by The Methodist Hospital Research Institute in Houston, Texas, with a sub-award to the University of...